Australia-based Mayne Pharma said it will spend $65 million to expand operations at its Greenville, NC, facility, including the construction of a 126,000-square-foot oral-dose facility.
The company said the expenditure will also include the repurposing of existing space to expand contract services.
The new facilities are expected to be fully operational by 2018 and will more than double Mayne's U.S. manufacturing capacity, the company said in a press release. Mayne currently employs 350 people in the state and anticipates hiring an additional 110 positions, including scientists and quality assurance specialists, when the project is complete.
"Once operational, the Company will be able to take on new and larger projects, and especially those that leverage our drug-delivery technologies and potent drug handling expertise," CEO Scott Richards said in a statement.
The new construction will be located on a campus that houses Mayne Pharma's products business, along with its contract development and manufacturing business, Metrics Contract Services. Founded in Greenville in 1994, Metrics began as a laboratory for analytical chemistry support services for pharmaceutical companies.
- read Mayne's release